{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:54:07Z","timestamp":1776300847363,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1124\/jpet.120.000040","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T15:36:46Z","timestamp":1596728206000},"page":"76-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial"],"prefix":"10.1016","volume":"375","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-2245","authenticated-orcid":false,"given":"K. Melissa","family":"Hallow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Boulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Penland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Helmlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily H.","family":"Nieves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00ebl H.","family":"van Raalte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiddo L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Greasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000040_bib1","doi-asserted-by":"crossref","first-page":"F618","DOI":"10.1152\/ajprenal.00421.2010","article-title":"Glomerular filtration rate determinations in conscious type II diabetic mice","volume":"300","author":"Bivona","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.120.000040_bib2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000040_bib3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1124\/jpet.120.000040_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1681\/ASN.2015111282","article-title":"MAP17 is a necessary activator of renal Na+\/glucose cotransporter SGLT2","volume":"28","author":"Coady","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.120.000040_bib5","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.120.000040_bib6","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.120.000040_bib7","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.120.000040_bib8","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE Study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.120.000040_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-015-0297-x","article-title":"Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus","volume":"14","author":"Fioretto","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/jpet.120.000040_bib10","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.2337\/diabetes.51.10.3090","article-title":"Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody","volume":"51","author":"Flyvbjerg","year":"2002","journal-title":"Diabetes"},{"key":"10.1124\/jpet.120.000040_bib11","first-page":"132","article-title":"SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration","volume":"63","author":"Fu","year":"2014","journal-title":"Diabetes"},{"key":"10.1124\/jpet.120.000040_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/00325481.2018.1423852","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"130","author":"Guthrie","year":"2018","journal-title":"Postgrad Med"},{"key":"10.1124\/jpet.120.000040_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/psp4.12177","article-title":"A quantitative systems physiology model of renal function and blood pressure regulation: application in salt-sensitive hypertension","volume":"6","author":"Hallow","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/jpet.120.000040_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/psp4.12178","article-title":"A quantitative systems physiology model of renal function and blood pressure regulation: model description","volume":"6","author":"Hallow","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/jpet.120.000040_bib15","doi-asserted-by":"crossref","first-page":"F819","DOI":"10.1152\/ajprenal.00497.2016","article-title":"Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis","volume":"312","author":"Hallow","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.120.000040_bib16","doi-asserted-by":"crossref","first-page":"F1295","DOI":"10.1152\/ajprenal.00202.2018","article-title":"Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data","volume":"315","author":"Hallow","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.120.000040_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.120.000040_bib18","doi-asserted-by":"crossref","first-page":"R647","DOI":"10.1152\/ajpregu.00039.2013","article-title":"A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model","volume":"306","author":"Hallow","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.120.000040_bib19","doi-asserted-by":"crossref","first-page":"e0141336","DOI":"10.1371\/journal.pone.0141336","article-title":"23Na magnetic resonance imaging of the lower leg of acute heart failure patients during diuretic treatment","volume":"10","author":"Hammon","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.000040_bib20","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.120.000040_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.120.000040_bib22","doi-asserted-by":"crossref","first-page":"6470137","DOI":"10.1155\/2018\/6470137","article-title":"Effect of tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus","volume":"2018","author":"Kamei","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1124\/jpet.120.000040_bib23","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.120.000040_bib24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.120.000040_bib25","doi-asserted-by":"crossref","first-page":"F430","DOI":"10.1152\/ajprenal.00010.2006","article-title":"Model of albumin reabsorption in the proximal tubule","volume":"292","author":"Lazzara","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.120.000040_bib26","doi-asserted-by":"crossref","first-page":"R1840","DOI":"10.1152\/ajpregu.00457.2007","article-title":"Modulation of single-nephron GFR in the db\/db mouse model of type 2 diabetes mellitus. II. Effects of renal mass reduction","volume":"294","author":"Levine","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.120.000040_bib27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000040_bib28","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.120.000040_bib29","first-page":"2","article-title":"Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice","volume":"5","author":"Mahato","year":"2018","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1124\/jpet.120.000040_bib30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/jpet.120.000040_bib31","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/01.hjh.0000133733.32125.09","article-title":"Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study","volume":"22","author":"Marre","year":"2004","journal-title":"J Hypertens"},{"key":"10.1124\/jpet.120.000040_bib32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1124\/jpet.120.000040_bib33","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000040_bib34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/jog.12280","article-title":"Post-partum recovery course in patients with gestational hypertension and pre-eclampsia","volume":"40","author":"Mikami","year":"2014","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1124\/jpet.120.000040_bib35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/jpet.120.000040_bib36","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/nep.13552","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: a comparison study with furosemide and tolvaptan","volume":"24","author":"Ohara","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1124\/jpet.120.000040_bib37","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000040_bib38","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.120.000040_bib39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2215\/CJN.10180916","article-title":"Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function","volume":"12","author":"Petrykiv","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.120.000040_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1525-139X.2009.00569.x","article-title":"Water-free sodium accumulation","volume":"22","author":"Titze","year":"2009","journal-title":"Semin Dial"},{"key":"10.1124\/jpet.120.000040_bib41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/01.mnh.0000441151.55320.c3","article-title":"Sodium balance is not just a renal affair","volume":"23","author":"Titze","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1124\/jpet.120.000040_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.120.000040_bib43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.120.000040_bib44","doi-asserted-by":"crossref","DOI":"10.2337\/db19-2343-PUB","article-title":"2343-PUB: reduction of HbA1c after SGLT2 inhibitors correlate with change in plasma osmolarity but not with elevation of hematocrit in Japanese patients with type 2 diabetes","volume":"68","author":"Wada","year":"2019","journal-title":"Diabetes"},{"key":"10.1124\/jpet.120.000040_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/psp4.12052","article-title":"A tutorial on RxODE: simulating differential equation pharmacometric models in R","volume":"5","author":"Wang","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/jpet.120.000040_bib46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000040_bib47","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.120.000040_bib48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000364909","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy","volume":"40","author":"Yamout","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1124\/jpet.120.000040_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13300-015-0150-y","article-title":"Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis","volume":"7","author":"Yavin","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1124\/jpet.120.000040_bib50","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:44:25Z","timestamp":1739965465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524270130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0022356524270130"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000040","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}